Diabetes Mellitus
Conditions
Keywords
Diabetes mellitus Type 1, Diabetes mellitus Type 2, blood glucose self-testing, non-invasive tissue glucose prediction, optical pain-free glucose testing
Brief summary
The CNOGA Combo Glucometer (CoG) employs an invasive glucose meter using blood glucose teststrips and requiering a capillary blood sample obtained from a fingerstick and in addition, a non-invasive optical component for prediction of tissue glucose at the fingertip. In this study, participants will use both devices during meal tests and also at home during routine care. The results from the device will be compared to a standard reference method and will be used to determine the accuracy of the two device components.
Detailed description
The trial starts with a screening and training visit (V1). This is followed by an individual calibration period for the non-invasive device component by means of multiple parallel measurements with the invasive and the noninvasive device component. This will be done by the participants at home. Thereafter, the participants will come to the study site and will ingest a standardized meal (V2). Blood will be drawn for assessment of HbA1c and biochemical safety parameters. During the next 3 hours, 11 fingersticks will be made to obtain capillary blood samples for comparator readings with the two CoG components and with a laboratory reference method (YSI gucose analyzer). The patients will now continue to use the devices at home for three months, but are not allowed to use any CoG result for treatment decisions. In an interim visit after 6 weeks (V3), blood will be drawrn for HbA1c and biochemical safety parameters and three comparison measurements will be made with the CoG device components and the laboratory reference method. At the final visit after 12 weeks (V4), the procedures of the first meal test visit (V2) will be repeated, which conludes that study. In addition, the participants will be asked to complete a device satisfaction questionnaire at V2, V3, and V4.
Interventions
DEVICEnon-invasive tissue glucose prediction
Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
Sponsors
Cnoga Medical Ltd.
Sciema UG
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients with Type 1 or Type 2 diabetes of Afro-American, Hispanic, or Asian-American origin * Subjects who are able to provide informed consent (by him/herself or by his/her guardian); * 18 years old and above; * HbA1c \< 10 % * Anatomically suitable finger as determined by the clinical investigator and detailed in section 4
Exclusion criteria
* Does not meet inclusion criteria; * Subjects requiring dialysis; * Any conditions that may hamper good visual contact between the finger and sensor, such as raised birthmarks, scars and/or tattoos; * Pregnancy; * Nursing mothers; * Any skin injuries on the measured finger; * Severe disease conditions (cancer etc.) * Any condition that may prevent patients from successful participation in the trial (in discretion of the investigator)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CoG accuracy in measuring glucose levels (non-invasively) during a standardized meal experiment. | Experiment will be performed twice within 3 months | Comparison of non-invasive CoG device measurements (tissue glucose in mg/dL) with the results of a standard laboratory reference method (YSI glucose analyzer, blood glucose in mg/dL) by consensus-error grid analysis |
| CoG accuracy in monitoring glucose levels (invasively) during a standardized meal experiment. | Experiment will be performed twice within 3 months | Comparison of CoG invasive device readings (blood glucose in mg/dL) with the results of a standard laboratory reference method (YSI glucose analyzer, blood glucose in mg/dL) by consensus-error grid analysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of the CoG on long-term (three month) glycemic control (HbA1c using standard laboratory procedures) in patients with type 1 and 2 diabetes | 3 months | Change in HbA1c from baseline after 6 weeks and 12 weeks |
| Treatment satisfaction questionnaire | 3 months | Change in device satisfaction questionnaire score after 6 weeks and 12 weeks |
Countries
United States
Outcome results
None listed